Lo Re Research Group
Dr. Lo Re is an Infectious Diseases physician and clinical epidemiologist. His areas of interest include epidemiology of hepatitis B and C virus infections, HIV-viral hepatitis coinfection, and drug-induced liver disease. Dr. Lo Re’s research has evaluated clinical outcomes of chronic viral hepatitis infection and treatment, particularly in the HIV population. He is currently examining risk factors and predictors of hepatic decompensation among HIV/hepatitis-coinfected patients in the Veterans Aging Cohort Study. He has examined extra-hepatic effects of chronic hepatitis infection, including cardiovascular disease and metabolic bone disease, in chronic hepatitis patients. Dr. Lo Re has also conducted research examining adherence to combination pegylated interferon and ribavirin therapy in both hepatitis C-monoinfected and HIV/hepatitis C-coinfected patients, specifically examining the levels of adherence required for maximal hepatitis C suppression, virologic response, changes in adherence over time, and risk factors for poor adherence to antiviral therapy. His ongoing work in the area of drug-induced liver disease focuses on identifying predictors of acute liver failure among patients with diagnoses of drug-induced hepatitis and evaluating the risk posed by medications within important drug classes of acute liver failure as well.
Dr. Lo Re is also interested in HIV/hepatitis B virus coinfection. His recent work in this area has focused on the prevalence, risk factors, and clinical significance of occult hepatitis B virus infection in HIV-infected patients.
From a methodologic standpoint, Dr. Lo Re’s research has also focused on developing methods to identify hepatic decompensation and acute liver failure events within population-based and administrative data sources. He is also the Workgroup leader for the Mini-Sentinel initiative to develop algorithms to identify severe acute liver injury among patients without pre-existing liver disease and with chronic hepatitis B and C within existing administrative databases. Dr. Lo Re is also developing methods to evaluate the safety of medications following market release.
Penn Medicine study suggests long-term suppression of hepatitis B in patients who are HIV-coinfected may lower cancer risk
May 21, 2021 | Press Release
Liver cancer linked to detectable HIV and lower CD4 count
March 11, 2019 | Full Article
Half of hepatitis C patients with private insurance denied life-saving drugs
June 7, 2018 | Press Release
37th International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE)
August 21-25, 2021
ID Week 2021
September 29-October 3, 2021